Clinical trial
Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer
NCT00377559 · Catharina Ziekenhuis Eindhoven, Other · Completed
Key facts
| NCT number | NCT00377559 |
|---|---|
| Title | Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer |
| Official title | Phase II Multicentre Open Label Trial Evaluating the Efficacy and Safety of the Liposomal Doxorubicin (Myocet®) and Docetaxel (Taxotere®) Combination as First-line Treatment of Patients With Metastatic HER2/Neu Negative Breast Cancer |
| Acronym | MYOTAX |
| Lead sponsor | Catharina Ziekenhuis Eindhoven, Other |
| Collaborators | Cephalon Industry Sanofi |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Non pegylated liposomal doxorubicin and docetaxel |
| Enrollment | 70 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Jul 1, 2011 |
| First posted | Sep 18, 2006 |
| Last update posted | Oct 6, 2015 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: